The U.S. Food and Drug Administration said on Sept. 9 the regulatory agency needs more time to decide whether e-cigarette maker Juul Labs Inc. and other major manufacturers can sell their products in the United States.
A U.S. appeals court on Aug. 26 threw out a $1.2 billion ruling against Gilead Sciences Inc., finding a patent on a cancer therapy the company was accused of infringing was invalid, in a blow to rival Bristol Myers Squibb Co.
Less than two months after life sciences giant Bayer acquired N.C.-based gene therapy company AskBio, the healthcare company launched a cell and gene therapy platform within its pharmaceutical division.
Catalyst Pharmaceuticals filed new patent infringement lawsuits against Jacobus Pharmaceuticals and PANTHERx Rare LLC over a treatment for the rare autoimmune disease Lambert-Eaton Myasthenic Syndrome (LEMS).
A federal judge dismissed Catalyst Pharmaceuticals’ lawsuit against the U.S. Food and Drug Administration regarding the approval of a rival drug for a rare autoimmune disease from New Jersey-based Jacobus Pharmaceutical.
A federal judge dismissed a challenge by hospital groups to a federal rule requiring them to disclose prices they quietly negotiate with insurers, in a victory for White House efforts to make healthcare pricing more transparent to patients.
A federal judge dismissed some of the criminal charges Elizabeth Holmes is facing.
The first of the Insys Therapeutics executives found guilty of violating the Racketeer Influenced and Corrupt Organizations (RICO) Act in May 2019 was sentenced to 33 months in federal prison.
Purchasers of Allergan Plc’s Namenda asked a federal judge to approve a $750 million settlement of claims that the drugmaker conspired to keep generic versions of the Alzheimer’s medication off the market.
A federal judge partially overturned the convictions of Insys Therapeutics Inc.’s founder and three former executives accused of bribing doctors to prescribe an addictive opioid, but declined to disturb the remainder of the jury’s verdict.